Pharmaceuticals company Innova Captab announced Q3FY25 results Revenue from Operations was Rs 316.5 crore in Q3FY25 vs Rs 302.5 crore Q3FY24, registering growth of 4.6%. EBITDA grew to Rs 50.9 crore vs Rs 46.9 crore last year. EBITDA Margins also improved to 16.1% vs 15.5% in Q3FY24. Profit after Tax improved significantly to Rs 34.2 crore vs Rs 25.1 crore (YoY growth of 36.3%). PAT Margins improved to 10.8% from 8.3%. Vinay Lohariwala, Managing Director, Innova Captab, said: “We are delighted to report a healthy performance in Q3 and 9MFY25, driven by robust resilience in our core business operations and strategic advancements. Our revenue from operations registered YoY growth of 4.6% in Q FY25 and of 13.5% in 9MFY25. PAT demonstrated strong surge of 36.3% in Q3FY25 and of 50.5% in 9MFY25. Key highlight of the quarter was the successful launch of operations at our new Kathua, Jammu facility, where we commenced commercial production on January 14, 2025. This milestone represents a pivotal moment in our growth trajectory, bolstering both our production capacity and our ability to meet the evolving demands of our customers. This expansion is a cornerstone of our long-term strategic vision, reinforcing our market position and laying the foundation for sustained, profitable growth. With the added advantage of incentives from the central government, we are optimistic about the positive impact on profitability from the Jammu operations. As we look to the future, we are confident in the continued strength and resilience of our business. With a diversified portfolio and a steadfast commitment to long-term value creation, our teams are united in executing our strategic priorities. We are well-positioned for sustained growth and are excited to build on this momentum in the years ahead.” Result PDF